Synonyms: AG-881 | AG881 | Voranigo®
vorasidenib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Vorasidenib (AG-881) inhibits mutant forms of the isocitrate dehydrogenases (IDH1 and IDH2) [4] that catalyse the generation of the oncogenic metabolite d-2-hydroxyglutarate (2-HG). This compound and others, and their use for treating cancer are claimed in patent US10028961 [5]. Vorasidenib can cross the blood-brain barrier, and is being proposed as a chemotherapeutic for IDH mutation +ve cancers including gliomas [3,9] and hematological malignancies [1]. X-ray cocrystal structures of vorasidenib with mutant IDH1 and mutant IDH2 have been deposited with the RCSB Protein Data Bank [4,6]. The X-ray structures show that vorasidenib binds at an allosteric pocket formed in IDH homodimers, at the interface of the two monomers.
|
|
Bioactivity Comments |
Vorasidenib inhibits IDH1R132H (dimerised with wild type IDH1) with an IC50 of 6 nM, and IDH2R140Q with an IC50 of 12 nM [4]. The IC50s for inhibition of wild type enzymes are not reported. In patients with IDH mutant-carrying gliomas vorasidenib lowers 2-HG levels by >90% [4]. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|